Abstract

Multidrug-resistant tuberculosis (MDR-TB) continues to be a global health problem. Data on rifampicin resistance MTB using Xpert- MTB/RIF assay in Ethiopia, particularly in the study area is limited. The aim of this study was to determine the frequency of MTB and rifampicin resistant-MTB among presumptive tuberculosis patients in Tigray, Northern Ethiopia. A multicenter retrospective study was conducted among presumptive TB patients from five governmental hospitals and one comprehensive specialized teaching hospital in Tigray regional state. Records of sputum sample results of presumptive MTB patients with Xpert-MTB/RIF assay from January 2016 to December 2019 were investigated. Data extraction tool was used to collect data from registration books and analyzed using SPSS ver.21 statistical software. Statistical significance was set at p-value ≤ 0.05. Of the 30,935 presumptive adult TB patients who have provided specimens for TB diagnosis from January 2016 to December 2019, 30,300 (98%) had complete data and were included in this study. More than half, 17,471 (57.7%) were males, and the age of the patients ranged from 18-112 years, with a median age of 40.65 (interquartile 29.4-56.5 years). Majority, 28,996 (95.7%) of the participants were treatment naïve, and 23,965 (79.1%) were with unknown HIV status. The overall frequency of MTB was 2,387 (7.9% (95% CI: 7.6-8.2%); of these, 215 (9% (95% CI: 7.9-10.2%) were rifampicin resistant-MTB. Age (18-29 years), HIV positive and previous TB treatment history were significantly associated with high MTB (p < 0.001), whereas gender (being female) was associated with low MTB (p < 0.001). Likewise, rifampicin resistant-MTB was more prevalent among relapse (p < 0.001) and failure cases (p = 0.025); while age group 30-39 years was significantly associated with lower frequency of rifampicin resistant-MTB (p = 0.008). Frequency of MTB among tuberculosis presumptive patients was low; however, the problem of rifampicin resistant-MTB among the tuberculosis confirmed patients was high. The high frequency of MTB and RR-MTB among previously treated and HIV positive patients highlights the need for more efforts in TB treatment and monitoring program in the study area.

Highlights

  • Tuberculosis (TB) is one the top ten causes of mortality and the first killer among infectious diseases worldwide

  • The aim of this study was to determine the frequency of Mycobacterium tuberculosis (MTB) and rifampicin resistant-MTB among presumptive tuberculosis patients in Tigray, Northern Ethiopia

  • Age (18–29 years), Human immunodeficiency virus (HIV) positive and previous TB treatment history were significantly associated with high MTB (p < 0.001), whereas gender was associated with low MTB (p < 0.001)

Read more

Summary

Introduction

Tuberculosis (TB) is one the top ten causes of mortality and the first killer among infectious diseases worldwide. Multidrug resistant Mycobacterium tuberculosis (MDR-MTB), defined as resistant to at least isoniazid and rifampicin, is a major global health problem. The WHO endorsed Xpert MTB/RIF assay in 2010, an automated molecular system which detects both DNA of MTB and rifampicin resistance (RR) simultaneously [4]. The assay was indicated for patients with TB/HIV co-infection, presumptive MDR-TB and paediatrics TB patients [6]. In Ethiopia Xpert- MTB/RIF assay was implemented in all general and referral hospitals since 2014 [8]. Multidrug-resistant tuberculosis (MDR-TB) continues to be a global health problem. Data on rifampicin resistance MTB using Xpert- MTB/RIF assay in Ethiopia, in the study area is limited. The aim of this study was to determine the frequency of MTB and rifampicin resistant-MTB among presumptive tuberculosis patients in Tigray, Northern Ethiopia

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call